Literature DB >> 31445172

Sequential tests of promise with discrete time-to-event data.

Bruce Levin1, Louise Kuhn2, Cheng-Shiun Leu3, Wei-Yann Tsai4.   

Abstract

We introduce a family of sequential test procedures in the context of a futility study design, or as we prefer to call it, a formal test of promise, suitable for use with time-to-event data. The procedures are motivated by an actual trial that was undertaken to test the promise of very early antiretroviral therapy to achieve viral remission in infants with perinatally-acquired HIV. Important gains in efficiency are illustrated in terms of early stopping and statistical power compared with other methods such as Simon's two-stage design with binary outcomes. We show how to calculate the operating characteristics of the proposed sequential tests of promise and provide optimal or near-optimal boundaries for small or medium size samples which provide the typical context for the tests under consideration. The design features discussed in this article are also of immediate pertinence to trials designed to test disease cures which may require treatment interruption and small numbers of participants.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ART cessation trials; Futility design; Non-superiority design; Simon's two-stage design; Survival data

Mesh:

Substances:

Year:  2019        PMID: 31445172      PMCID: PMC6815733          DOI: 10.1016/j.cct.2019.105818

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  11 in total

1.  The need for treatment interruption studies and biomarker identification in the search for an HIV cure.

Authors:  Jonathan Z Li; Davey M Smith; John W Mellors
Journal:  AIDS       Date:  2015-07-31       Impact factor: 4.177

2.  The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies.

Authors:  Golnaz Namazi; Jesse M Fajnzylber; Evgenia Aga; Ronald J Bosch; Edward P Acosta; Radwa Sharaf; Wendy Hartogensis; Jeffrey M Jacobson; Elizabeth Connick; Paul Volberding; Daniel Skiest; David Margolis; Michael C Sneller; Susan J Little; Sara Gianella; Davey M Smith; Daniel R Kuritzkes; Roy M Gulick; John W Mellors; Vikram Mehraj; Rajesh T Gandhi; Ronald Mitsuyasu; Robert T Schooley; Keith Henry; Pablo Tebas; Steven G Deeks; Tae-Wook Chun; Ann C Collier; Jean-Pierre Routy; Frederick M Hecht; Bruce D Walker; Jonathan Z Li
Journal:  J Infect Dis       Date:  2018-11-05       Impact factor: 5.226

3.  Early antiretroviral therapy in children perinatally infected with HIV: a unique opportunity to implement immunotherapeutic approaches to prolong viral remission.

Authors:  Nigel Klein; Paolo Palma; Katherine Luzuriaga; Savita Pahwa; Eleni Nastouli; Diane M Gibb; Pablo Rojo; William Borkowsky; Stefania Bernardi; Paola Zangari; Vincent Calvez; Alexandra Compagnucci; Britta Wahren; Caroline Foster; María Ángeles Munoz-Fernández; Anita De Rossi; Jintanat Ananworanich; Deenan Pillay; Carlo Giaquinto; Paolo Rossi
Journal:  Lancet Infect Dis       Date:  2015-07-14       Impact factor: 25.071

Review 4.  Antiretroviral treatment in HIV-infected infants and young children: novel issues raised by the Mississippi baby.

Authors:  Stephanie Shiau; Louise Kuhn
Journal:  Expert Rev Anti Infect Ther       Date:  2014-02-09       Impact factor: 5.091

5.  Optimal two-stage designs for phase II clinical trials.

Authors:  R Simon
Journal:  Control Clin Trials       Date:  1989-03

6.  Absence of detectable HIV-1 viremia after treatment cessation in an infant.

Authors:  Deborah Persaud; Hannah Gay; Carrie Ziemniak; Ya Hui Chen; Michael Piatak; Tae-Wook Chun; Matthew Strain; Douglas Richman; Katherine Luzuriaga
Journal:  N Engl J Med       Date:  2013-10-23       Impact factor: 91.245

7.  The futility study--Progress over the last decade.

Authors:  Bruce Levin
Journal:  Contemp Clin Trials       Date:  2015-06-26       Impact factor: 2.226

8.  Rapid decline of HIV-1 DNA and RNA in infants starting very early antiretroviral therapy may pose a diagnostic challenge.

Authors:  Kirsten A Veldsman; Jean Maritz; Shahieda Isaacs; Mary G Katusiime; Anita Janse van Rensburg; Barbara Laughton; John W Mellors; Mark F Cotton; Gert U van Zyl
Journal:  AIDS       Date:  2018-03-13       Impact factor: 4.177

9.  Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection.

Authors:  Genevieve E Martin; Morgane Gossez; James P Williams; Wolfgang Stöhr; Jodi Meyerowitz; Ellen M Leitman; Philip Goulder; Kholoud Porter; Sarah Fidler; John Frater
Journal:  AIDS       Date:  2017-02-20       Impact factor: 4.177

10.  Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study.

Authors:  Asier Sáez-Cirión; Charline Bacchus; Laurent Hocqueloux; Véronique Avettand-Fenoel; Isabelle Girault; Camille Lecuroux; Valerie Potard; Pierre Versmisse; Adeline Melard; Thierry Prazuck; Benjamin Descours; Julien Guergnon; Jean-Paul Viard; Faroudy Boufassa; Olivier Lambotte; Cécile Goujard; Laurence Meyer; Dominique Costagliola; Alain Venet; Gianfranco Pancino; Brigitte Autran; Christine Rouzioux
Journal:  PLoS Pathog       Date:  2013-03-14       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.